PB 114 of 2020
National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 10)
I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health make the following determination.
Dated 26th November 2020
THEA CONNOLLY
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
2 Commencement
3 Authority
4 Schedule
Schedule 1—Amendments 2
National Health (Continued Dispensing - Emergency Measures) Determination 2020 2
(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 10).
(2) This instrument may also be cited as PB 114 of 2020.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 December 2020. |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 89A(3) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Continued Dispensing – Emergency Measures) Determination 2020
[1] Schedule 1, after entry for Beclometasone in the form Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation)
insert:
Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose | Inhalation by mouth |
[2] Schedule 1, after entry for Norethisterone with ethinylestradiol in the form Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets
insert:
| Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets USP | Oral |
[3] Schedule 1, after entry for Paracetamol in the form Suppositories 500 mg, 24
insert:
| Suppository 500 mg | Rectal |
[4] Schedule 1, entry for Posaconazole
omit:
| Oral suspension 40 mg per mL, 105 mL | Oral |
[5] Schedule 1, after entry for Protein formula with carbohydrate, fat, vitamins and minerals
insert:
Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A | Oral liquid 125 mL, 24 (Renastep) | Oral |
[6] Schedule 1, after entry for Ranitidine in the form Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL
insert:
| Tablet 150 mg (as hydrochloride) | Oral |
[7] Schedule 1, entry for Ranitidine
omit:
| Tablet, effervescent, 150 mg (as hydrochloride) | Oral |
[8] Schedule 1, entry for Rivaroxaban
insert as first entry:
| Tablet 2.5 mg | Oral |